Immunotherapy Expert Dr. Brian Barnett Joins OncBioMune Scientific Advisory Board

BATON ROUGE, LA--(Marketwired - October 24, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce that, effective immediately, Dr. Brian Barnett has joined the OncBioMune Scientific Advisory Board.

Dr. Barnett currently serves as Senior Medical Director, Neratinib, Medical Affairs at Puma Biotechnology. Prior to accepting his position at Puma Biotechnology, Dr. Barnett held numerous senior level positions at Roche Group subsidiary Genentech providing oversight in the FDA approval and launch of the potential blockbuster breast cancer drug Kadcyla. These positions at Genentech included Associate Medical Director, Kadcyla, U.S. Medical Affairs; Medical Director, Kadcyla, U.S. Medical Affairs; and Medical Director, Kadcyla, Global Product Development Oncology. Before his time at Genentech, Dr. Barnett served as Director of Medical Oncology at the Elliott, Barnett, Head Breast Cancer Research and Treatment Center.

Throughout his career, Dr. Barnett has authored and been integral to many peer-reviewed publications on immunotherapy and delivered oral and poster presentations at leading oncology conferences on regulating cancer with immunotherapy approaches.

Dr. Barnett earned a Bachelor of Science (BS) degree in Chemistry from Millsaps College, a Doctor of Medicine (MD) degree from the University of Mississippi School of Medicine and completed his medical training as a Fellow, Hematology and Medical Oncology at Tulane University Health Sciences Center. He is an active member of the American Association of Cancer Research and the American Society of Clinical Oncology.

"I'm well aware of the potential of the vaccine technology that OncBioMune is developing after working closely with Drs. Head and Elliott at their breast cancer center," said Dr. Barnett. "I am impressed with what I see in the clinical data of ProscaVax as a novel prostate cancer vaccine and look forward to sharing my clinical experiences going forward as ProscaVax commences mid-stage studies."

"On behalf of our entire team, I'd like to formally welcome Dr. Barnett to our Scientific Advisory Board," said Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "Brian is highly-respected as a thought leader in the immunotherapy space and brings years of highly relevant experience to our team in Phase 2 and Phase 3 clinical research. His knowledge and network will be a invaluable assets as we move forward with not only ProscaVax, but our entire pipeline."

Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax® is scheduled to commence a Phase 2 clinical study in 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor will there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.